Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 1/20 | 0.40 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.36 |
| ▸ | CALML3 | P27482 | 2/20 | 0.35 |
| ▸ | MAOA | P21397 | 12/20 | 0.34 |
| ▸ | GRM5 | P41594 | 3/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL412775 | 0.88 | CYP2E1 (0.40) | TDO2CYP2E1CALML3MAOAGRM5 | |
| SCHEMBL412857 | 0.88 | GRM5 (0.35) | CYP2E1CALML3MAOAGRM5CYP2C9 | |
| SCHEMBL412657 | 0.88 | CALML3 (0.51) | CALML3MAOACYP2C9CYP2C19MAOB | |
| SCHEMBL412771 | 0.88 | CNR2 (0.39) | CYP2E1CALML3MAOAGRM5CYP2C9 | |
| SCHEMBL412753 | 0.86 | CALML3 (0.48) | TDO2CALML3MAOACYP2C9CYP2C19 | |
| SCHEMBL463337 | 0.85 | CYP2E1 (0.52) | TDO2CYP2E1CALML3MAOACYP2C9 | |
| SCHEMBL412646 | 0.85 | TDO2 (0.42) | TDO2CALML3MAOAGRM5CYP2C9 | |
| SCHEMBL412083 | 0.85 | TDO2 (0.40) | TDO2CALML3MAOACYP2C9CYP2C19 | |
| SCHEMBL411619 | 0.84 | GRM2 (0.40) | TDO2CALML3GRM5 | |
| SCHEMBL412794 | 0.84 | TDO2 (0.46) | TDO2CALML3MAOACYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065170-A1 | Antimicrobial Cyclocarbonyl Heterocyclic Compounds For Treatment Of Bacterial Infections | MICURX PHARMACEUTICALS, INC. (KY) | 2012-03-15 | — | — | US | disclosed |
| US-20120065170-A1 | Antimicrobial Cyclocarbonyl Heterocyclic Compounds For Treatment Of Bacterial Infections | MICURX PHARMACEUTICALS, INC. (KY) | 2012-03-15 | — | — | US | disclosed |
| WO-2012033952-A1 | 3 - PHENYL- 2 -OXO- 1, 3 -OXAZOLIDINES FOR TREATMENT OF BACTERIAL INFECTIONS | MICURX PHARMACEUTICALS, INC. (KY) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065170-A1 | Antimicrobial Cyclocarbonyl Heterocyclic Compounds For Treatment Of Bacterial Infections | NISCH, SI, VIP | TDO2 183/4885CYP2E1 352/4885CALML3 1652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.